Real World Data

Approaches powered by RWD can clear the way for a greater focus on patient-centered care.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

A multi-national study reveals over half of older adults in several European countries are prescribed five or more medications—spotlighting the urgent need for better data-driven prescribing strategies.

By embracing practical, human-centered use cases, life sciences companies are breaking free from GenAI “pilotitis” and demonstrating how scalable AI solutions can help transform patient care and provider efficiency.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, explains how he anticipates the evolving regulatory environment impacting the future of pharmaceutical development, especially in the context of emerging technologies like AI.

Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.